IP Library Granted Patent US 12,152,252
Granted Patent B2
US 12,152,252 · App. 16/480,273 · Granted Nov 26, 2024

Systems and methods for immunomodulation of mucosal-associated invariant T cells

Inventors: Martin Prlic (Seattle, WA); Julia Berkson (Seattle, WA); Chloe Slichter (Seattle, WA)
Assignee: Fred Hutchinson Cancer Center
C12N5/0638C12Q1/6876G01N33/68C12N2500/30C12N2501/2312C12N2501/2315C12N2501/2318C12N2501/50C12N2501/998C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,152,252
App. No.
16/480,273
Granted
Nov 26, 2024
Kind
B2
Abstract

Systems and methods to modulate the function of mucosal-associated invariant T (MAIT) cells in the absence of a T cell receptor (TCR) signal are described. The systems and methods can be used to elucidate the function of MAIT cells to assess potential therapeutic strategies for conditions associated with inflammation.

Claims (11)

1. A method comprising:

inducing expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4) on mucosal-associated invariant T (MAIT) cells in the absence of a T cell receptor (TCR) signal by incubating the MAIT cells in a single culture media with an effective amount of each of interleukin (IL)-12, IL-15, IL-18, and an anti-MR1 antibody for an effective duration of time, thereby inducing the expression of the CTLA-4 on the MAIT cells in the absence of the TCR signal; and

measuring the expression of the CTLA-4 on the MAIT cells after the inducing.

2. The method of claim 1 , wherein the effective amount of IL-12 is 100 ng/ml, the effective amount of IL-15 is 100 ng/ml, and the effective amount of IL-18 is 100 ng/mL.

3. The method of claim 1 , wherein the effective amount of the anti-MR1 antibody is 50 μg/mL.

4. The method of claim 1 , wherein the effective duration of time is 24 hours.

5. The method of claim 1 , wherein the effective duration of time is at least 24 hours.

6. The method of claim 1 , wherein the MAIT cells are in a population of mononuclear cells.

7. The method of claim 1 , wherein the MAIT cells are CD3 + CD4 − CD8 + Vα7.2 + CD161 hi .

8. The method of claim 1 , wherein the MAIT cells are CD8 + CD161 hi CCR6 hi CD62L lo .

9. The method of claim 1 , wherein the single culture media comprises RPMI 1640 supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin sulfate, and 10% FBS.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jun 23, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060438/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2019
From: PRLIC, MARTIN; BERKSON, JULIA; SLICHTER, CHLOE
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 050122/0793 →
Continuity (2)
Provisional Application 62449494 · Jan 23, 2017
Related Publication 20190382725A1 · Dec 19, 2019